ArticleBlood2019
PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 91 citations in OpenAlex.
- Protein tyrosine kinase-6 is post-translationally regulated by arginine methylation and ubiquitination.Cell death & disease · 2026Article
- Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics.Nature cancer · 2026Article
- PRMT1 facilitates the tumorigenesis of chronic lymphocytic leukemia by regulating methylation of MAST1.Leukemia · 2026Article
- Targeting the PRMT1 axis in cancer: from epigenetic plasticity to contextual therapeutic interventions.Frontiers in oncology · 2026Review
- PRMT1 in Health and Disease: Emerging Perspectives From Molecular Mechanisms to Therapeutic Strategies.MedComm · 2025Review
- PRMT1 promotes immune escape in hepatocellular carcinoma by regulating arginine methylation modification of MYC protein.Epigenetics · 2025Article
- Arginine methylation in cancer: mechanisms and therapeutic implications.Biomarker research · 2025Review
- The Role of Protein Arginine Methylation as a Post-Translational Modification in Cellular Homeostasis and Disease.Biology · 2025Review
- Article
- Establishment of CD34 + hematopoietic stem cell-derived xenograft model of hyperleukocytic acute myeloid leukemia.BMC cancer · 2025Article
- PRMT1 Promotes the Self-renewal of Leukemia Stem Cells by Regulating Protein Synthesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- PRMT3 and CARM1: Emerging Epigenetic Targets in Cancer.Journal of cellular and molecular medicine · 2025Review
- TRIM21-mediated PRMT1 degradation attenuates colorectal cancer malignant progression.Cell death & disease · 2025Article
- Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia.Leukemia · 2025Article
- Targeting splicing for hematological malignancies therapy.BMC genomics · 2024Review
- Phase separation of PML/RARα and BRD4 coassembled microspeckles governs transcriptional dysregulation in acute promyelocytic leukemia.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Alkynyl nicotinamides show antileukemic activity in drug-resistant acute myeloid leukemia.The Journal of clinical investigation · 2024Article
- Article
- Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity.Nature cancer · 2024Article
- PRMT1 in human neoplasm: cancer biology and potential therapeutic target.Cell communication and signaling : CCS · 2024Review
Corrections and comments
- Commented on by
Authors and funding
33 authors at 10 institutions in 2 countries.
Xin HeDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Yinghui ZhuDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Yi-Chun LinCollege of Pharmacy, Western University of Health Sciences, Pomona CA.
Min LiDepartment of Information Sciences and.
Juan DuThe Integrative Genomics Core, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Haojie DongDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Jie SunDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Lei ZhuDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Hanying WangDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Zonghui DingDepartment of Biochemistry and Molecular Biology, Mayo Clinic Arizona, Scottsdale, AZ.
Lei ZhangTranslational Biomarker Discovery Core and.
Lianjun ZhangDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Dandan ZhaoDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Zhihao WangDepartment of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Herman WuDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Han ZhangCollege of Pharmacy, Western University of Health Sciences, Pomona CA.
Wenjuan JiangCollege of Pharmacy, Western University of Health Sciences, Pomona CA.
Yang XuDepartment of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jian JinDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
Yudao ShenDepartment of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
Jeff PerryDepartment of Biochemistry, University of California, Riverside, CA.
Xinyang ZhaoDepartment of Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL.
Bin ZhangDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Songbai LiuSuzhou Key Laboratory for Medical Biotechnology, Suzhou Vocational Health College, Suzhou, China.
Sheng-Li XueDepartment of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; and.
Binghui ShenDepartment of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Chun-Wei ChenDepartment of Systems Biology and.
Jianjun ChenDepartment of Systems Biology and.
Samer KhaledDepartment of Hematology and Hematopoietic Cell Transplantation (HCT), Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Ya-Huei KuoDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Guido MarcucciDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Yun LuoCollege of Pharmacy, Western University of Health Sciences, Pomona CA.
Ling LiDepartment of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematologic Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope Medical Center, Duarte, CA.
Beckman Research InstituteCity of Hope · USWestern University of Health Sciences · USIcahn School of Medicine at Mount Sinai · USFirst Affiliated Hospital of Soochow University · CNMayo Clinic in Arizona · USSecond Affiliated Hospital of Zhejiang University · CNSuzhou Vocational Health College · CNUniversity of Alabama at Birmingham · USUniversity of California, Riverside · US
Funding
Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3MVirology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9MFunction Analysis of FEN-1 Nuclease in Genome StabilityR01CA073764 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI BINGHUI SHEN · 2002 to 2026
$7.9MTargeting FTO to treat acute myeloid leukemiaR01CA243386 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2020 to 2024
$2.8MCombinational Targeting the Feed-forward Epigenetic Circuitry in Mixed Lineage LeukemiaR37CA233691 · NCI · MAYO CLINIC ROCHESTER · PI CHEN, CHUN-WEI DAVID · 2019 to 2025
$2.8MThe role and mechanism of METTL3/METTL14-mediated RNA modification in the pathogenesis and drug-resistance of AMLR01CA236399 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, JIANJUN · 2019 to 2023
$2.3MTargeting TET1 signaling to treat acute myeloid leukemiaR01CA211614 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.3MRole of BAZ2A in MLL-r leukemia and therapeutic responseR01CA236626 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, CHUN-WEI DAVID · 2019 to 2023
$2.2MTargeting protein acetylation as a therapeutic approach for MDSR01HL141336 · NHLBI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI LI, LING · 2018 to 2022
$2.2MThe role and mechanism of FTO in leukemogenesis and drug responseR01CA214965 · NCI · UNIVERSITY OF CINCINNATI · PI CHEN, JIANJUN · 2017 to 2021
$2.1MEpigenetic mechanisms for oncogene silencing in MLL-rearranged leukemiaR00CA197498 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI CHEN, CHUN-WEI DAVID · 2017 to 2019
$747kNCI NIH HHS P30 CA033572NCI NIH HHS R00 CA197498NCI NIH HHS R01 CA073764NCI NIH HHS R01 CA211614NCI NIH HHS R01 CA214965NCI NIH HHS R01 CA236399NCI NIH HHS R01 CA236626NCI NIH HHS R01 CA243386NCI NIH HHS R37 CA233691NHLBI NIH HHS R01 HL141336NIAID NIH HHS P30 AI028697
Abstract
The presence of FMS-like receptor tyrosine kinase-3 internal tandem duplication (FLT3-ITD) mutations in patients with acute myeloid leukemia (AML) is associated with poor clinical outcome. FLT3 tyrosine kinase inhibitors (TKIs), although effective in kinase ablation, do not eliminate primitive FLT3-ITD
Indexed as
Gene DuplicationAnimalsArginineBiomarkers, TumorCatalysisDisease Models, Animalfms-Like Tyrosine Kinase 3Gene Expression ProfilingHumansLeukemia, Myeloid, AcuteMethylationMiceMice, KnockoutModels, MolecularPrognosisProtein-Arginine N-MethyltransferasesArginineBiomarkers, TumorFLT3 protein, humanfms-Like Tyrosine Kinase 3PRMT1 protein, humanProtein-Arginine N-MethyltransferasesProtein Kinase InhibitorsRepressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.